Gefitinib and erlotinib

Table 1 Cell growth inhibition by lapatinib, gefitinib, and erlotinib [69] ...

A central and as yet poorly understood concept in the arena of gefitinib and erlotinib pharmacology is the cellular and biochemical basis for sensitivity to these inhibitors. Early functional analyses of the mutant receptors in cell-based kinase assays had suggested they exhibit an approximately ten-fold increased sensitivity to inhibition by gefitinib relative to wild-type EGFR (45,55). 

Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl AcadSci USA 2004 101 13306-13311. 

Neeman M et al. (2011) A LC-MS/MS for the assay of verumafenib, bosutinib, gefitinib and erlotinib in plasma from cancer patients, Master thesis, School of Pharmaceutical Sciences, University of Geneva and Lausanne, Switzerland... 

---